(Q38864797)

7 September 2017

1 reference

title

Update on Biologic Therapies for Systemic Lupus Erythematosus (English)

1 reference

systemic lupus erythematosus

7 September 2017

main subject

0 references

author

Helena Hiemisch Lobo Borba

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Roberto Pontarolo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

4

Shirley Ramos da Rosa Utiyama

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Andreas Funke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Astrid Wiens

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Cássio Marques Perlin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

publication date

1 July 2016

1 reference

Current Rheumatology Reports

7 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27299782%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11926-016-0589-5

8 June 2020

exact match

0 references

cites work

Systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Unmet medical needs in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Pathogenesis of systemic lupus erythematosus (SLE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Biological therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Pathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

New developments in Toll-like receptor targeted therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Targeted therapies in systemic lupus erythematosus: successes, failures and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Treatment of severe lupus nephritis: the new horizon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Mortality and causes of death in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Mortality in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

The anti-DNA antibody: origin and impact, dogmas and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Abetimus sodium: a medication for the prevention of lupus nephritis flares

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Defective B cell tolerance checkpoints in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Future prospects in biologic therapy for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

BLyS--an essential survival factor for B cells: basic biology, links to pathology and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Novel evidence-based systemic lupus erythematosus responder index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

The role of Tumor Necrosis Factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Blockade of interferon-γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

The soluble CD40 ligand sCD154 in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Role of TWEAK in lupus nephritis: a bench-to-bedside review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

The weight of interleukin-6 in B cell-related autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Reply to eLetter by Feldtkelleret al

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0589-5

Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.

21 January 2018

1 reference

12 December 2020

Systemic lupus erythematosus in the elderly

1 reference

12 December 2020

Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.

1 reference

12 December 2020

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

1 reference

12 December 2020

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

1 reference

12 December 2020

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

1 reference

12 December 2020

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice

1 reference

12 December 2020

A TWEAK in lupus nephritis

1 reference

12 December 2020

Which dose of steroids and which cytotoxics for severe lupus?

1 reference

12 December 2020

Treatment of systemic lupus erythematosus with LJP 394.

1 reference

12 December 2020

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

1 reference

12 December 2020

Anti-TNF-alpha therapies in systemic lupus erythematosus

1 reference

12 December 2020

Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients

1 reference

12 December 2020

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

1 reference

12 December 2020

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus

1 reference

12 December 2020

Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus

1 reference

12 December 2020

Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition

1 reference

12 December 2020

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

12 December 2020

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

1 reference

12 December 2020